GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Consensus Target Price of $56.50

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have received a consensus recommendation of “Hold” from the eleven analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $56.50.

A number of analysts have weighed in on GSK shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of GSK in a research report on Thursday, July 30th. HSBC reiterated a “hold” rating on shares of GSK in a research note on Thursday, September 10th. Citigroup assumed coverage on GSK in a report on Friday, July 24th. They set a “neutral” rating on the stock. Jefferies Financial Group upgraded GSK to a “strong-buy” rating in a research report on Friday, July 17th. Finally, Royal Bank Of Canada assumed coverage on GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company.

GSK Stock Performance

NYSE GSK opened at $47.16 on Friday. The firm has a 50-day moving average price of $50.69 and a two-hundred day moving average price of $52.08. GSK has a 12-month low of $42.85 and a 12-month high of $61.69. The company has a market capitalization of $95.38 billion, a P/E ratio of 14.75, a P/E/G ratio of 2.02 and a beta of 0.33. The company has a quick ratio of 0.52, a current ratio of 0.82 and a debt-to-equity ratio of 0.81.

GSK (NYSE:GSK) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.27 by $0.09. The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the firm earned $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Analysts anticipate that GSK will post 4.81 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Investors of record on Friday, August 14th will be issued a $0.4515 dividend. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date is Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a yield of 3.8%. GSK’s dividend payout ratio (DPR) is 55.63%.

Institutional Investors Weigh In On GSK

Several hedge funds have recently added to or reduced their stakes in the business. Kahn Brothers Group Inc. bought a new stake in shares of GSK during the 2nd quarter valued at $8,305,000. Nvest Financial LLC bought a new position in shares of GSK in the 2nd quarter worth about $2,236,000. Keystone Financial Planning Inc. increased its stake in shares of GSK by 3,114.8% in the 2nd quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after acquiring an additional 189,506 shares in the last quarter. Dorsey Wright & Associates purchased a new position in GSK during the 1st quarter valued at about $2,522,000. Finally, NewEdge Advisors LLC lifted its position in GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after acquiring an additional 852,437 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.